Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher
This article was originally published in The Pink Sheet Daily
Executive Summary
Alirocumab was associated with lower rate of major cardiovascular events compared to placebo in post-hoc, interim Phase III analysis – boosting chances for FDA approval in 2015. The firm is taking no chances on review period, purchasing a priority review voucher from BioMarin.
You may also be interested in...
Deal Watch: AbbVie Pays Highest Price Yet Seen For Priority Review Voucher
Depomed deems increased buyout offer from Horizon as insufficient, possibly leaving Horizon to consider alternative acquisitions. Valeant will pay $1bn to acquire Sprout and its just approved female sexual desire disorder drug Addyi.
AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?
With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.
Educational Efforts Are First Front Of Marketing Battle For PCSK9s
With reams of PCSK9 data showing robust lowering of LDL – a trusted surrogate – under their belt, sponsors aim to win over prescribers, payers and patients ahead of outcomes trial releases.